Asacol and Bc drug interactions - a phase IV clinical study of FDA data
Summary:
We study 20,688 people who take Asacol (mesalamine) and Bc (sodium sulfate; potassium sulfate; magnesium sulfate). There is no drug interaction reported.
The study analyzes what interactions people have when they take Asacol and Bc. It is created by eHealthMe based on reports the from the FDA, and is updated regularly.
What is Asacol?
Asacol has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 20,618 Asacol users. Check the latest studies of Asacol.
What is Bc?
Bc has active ingredients of sodium sulfate; potassium sulfate; magnesium sulfate. eHealthMe is studying from 70 Bc users. Check the latest studies of Bc.
No report is found.
Do you take Asacol and Bc?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Related publications that referenced our studies
- Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
- Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on mesalamine and sodium sulfate; potassium sulfate; magnesium sulfate (the active ingredients of Asacol and Bc, respectively), and Asacol and Bc (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Transitional Cell Carcinoma and Malignant Neoplasm Progression - 5 seconds ago
- Could Palbociclib cause Malignant Neoplasm Progression? - 8 seconds ago
- Could Lomotil cause Malignant Neoplasm Progression? - 11 seconds ago
- Could Diphenhydramine Hydrochloride cause Gout? - 11 seconds ago
- Could Effexor cause Nuclear Magnetic Resonance Imaging Brain Abnormal? - 11 seconds ago
- Could Revlimid cause Quality Of Life Decreased? - 16 seconds ago
- Could Tysabri cause Appendiceal Abscess? - 18 seconds ago
- Glioblastoma and Malignant Neoplasm Progression - 23 seconds ago
- Drug interactions of Ranexa and Effient - 26 seconds ago
- Drug interactions of Cartia Xt and Fentanyl - 27 seconds ago